GeoMx® Immune Pathways Panel

Helping Your Research

Targeted Content for Cancer Biology

The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status.

Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler (DSP).

How it Works

About
GeoMx® Immune Pathways Panel
About

The Immune Pathways panel contains 84 targets plus controls designed for broad coverage of the tumor and tumor microenvironment. GeoMx RNA assays contain in situ hybridization (ISH) probes conjugated to unique DNA indexing-oligonucleotides via a UV-photocleavable linker. After region of interest (ROI) selection on GeoMx DSP and UV cleavage of the oligonucleotides, each DNA oligonucleotide is recognized by a unique Reporter probe that contains a fluorescent barcode. Reporter probes are imaged and counted by the nCounter® Analysis System to provide a direct, digital readout of spatially resolved RNA expression.

  • Curated content designed for immuno-oncology research
  • Includes tumor and tumor microenvironment coverage plus the Tumor Inflammation Signature (TIS)
  • Pre-validated in multiplex format for use in human FFPE or fresh frozen tissue
  • Compatible with RNAscope® and antibody morphology markers for tissue imaging
  • Customizable with up to 10 additional targets of interest
  • For use with nCounter readout and compatible with DSP Data Center
GeoMx® Immune Pathways Panel

Curated Content for Immuno-Oncology

The GeoMx Immune Pathways panel is designed to profile key aspects of the tumor and tumor microenvironment biology.

  • Profile the global immune response
  • Assess microenvironment immune activity
  • Quantify tumor reactivity
  • Measure the 18-gene Tumor Inflammation Signature known to be associated with response to PD-1/PD-L1 inhibitor pathway blockade

Accompanying Morphology Marker Kits are available for tissue visualization and ROI selection.

Reagent Planning Tool

Find the perfect GeoMx DSP Reagent Planning Tool

Start Planning

Publications

View All Publications

Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer

BACKGROUND: Tertiary Lymphoid Structures (TLS) correlate with positive outcomes in patients with NSCLC and the efficacy of immune checkpoint blockade (ICB) in cancer. The actin regulatory protein hMENA undergoes tissue-specific splicing, producing the epithelial hMENA(11a) linked to favorable prognosis in early NSCLC, and the mesenchymal hMENADeltav6 found in invasive cancer cells and pro-tumoral cancer-associated fibroblasts (CAFs).

Whole transcriptome profiling of placental pathobiology in SARS‐CoV‐2 pregnancies identifies placental dysfunction signatures

Objectives: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) virus infection in pregnancy is associated with higher incidence of placental dysfunction, referred to by a few studies as a ‘preeclampsia‐like syndrome’. However, the mechanisms underpinning SARS‐CoV‐2‐induced placental malfunction are still unclear.

A Novel Approach for Pancreas Transcriptomics Reveals the Cellular Landscape in Homeostasis and Acute Pancreatitis

Background & aims: Acinar cells produce digestive enzymes that impede transcriptomic characterization of the exocrine pancreas. Thus, single-cell RNA-sequencing (scRNA-seq) studies of the pancreas underrepresent acinar cells relative to histological expectations, and a robust approach to capture pancreatic cell responses in disease states is needed.

Related Resources

See All Resources
Product Bulletin GeoMx® RNA Panel for Immuno-Oncology — Product Bulletin
Brochure/eBook GeoMx DSP – Brochure
Report DSP TAP Sample Report

Request a Quote

Contact our helpful experts and we’ll be in touch soon.